·   Log in

Archive for April 15th, 2010

Hepatitis C drug VX-222 lowers viral levels in early human trials: Vertex

Thursday, April 15, 2010 22:17

An investigational oral hepatitis C virus (HCV) polymerase inhibitor VX-222 developed by Vertex Pharmaceuticals has been seen reducing the viral load considerably.

This was posted under category: Clinical Trials  |  Read Full Story  |  0 Comments
Tagged with: ,

Once-a-day lixisenatide reduces HbA1c levels in diabetes: sanofi-aventis

Thursday, April 15, 2010 22:08

Lixisenatide, an investigational once-a-day drug therapy by sanofi-aventis, has been found successful in cutting down HbA1c levels during late phase clinical studies in diabetes patients.

This was posted under category: Uncategorized  |  Read Full Story  |  0 Comments
Tagged with: ,

Amoxicillin and clavulanate suspension recall may further strain Ranbaxy-US FDA relations

Thursday, April 15, 2010 22:03

Daiichi-Ranbaxy Laboratories has recalled two lots of the antibiotic amoxicillin and clavulanate potassium suspension from the US market following certain quality concerns.

This was posted under category: Featured, Industry  |  Read Full Story  |  0 Comments